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Abstract
Background: Vietnam is ranked 14th among 27 countries with high burden of multidrug-resistant tuberculosis
(MDR-TB). In 2009, the Vietnamese government issued a policy on MDR-TB called Programmatic Management of
Drug-resistant Tuberculosis (PMDT) to enhance and scale up diagnosis and treatment services for MDR-TB. Here we
assess the PMDT performance in 2013 to determine the challenges to the successful identification and enrollment
for treatment of MDR-TB in Vietnam.
Methods: In 35 provinces implementing PMDT, we quantified the number of MDR-TB presumptive patients tested
for MDR-TB by Xpert MTB/RIF and the number of MDR-TB patients started on second-line treatment. In addition,
existing reports and documents related to MDR-TB policies and guidelines in Vietnam were reviewed,
supplemented with focus group discussions and in-depth interviews with MDR-TB key staff members.
Results: 5,668 (31.2 %) of estimated 18,165 MDR-TB presumptive cases were tested by Xpert MTB/RIF and second-line
treatment was provided to 948 out of 5100 (18.7 %) of MDR-TB patients. Those tested for MDR-TB were 340/3224
(10.5 %) of TB-HIV co-infected patients and 290/2214 (13.1 %) of patients who remained sputum smear-positive after 2
and 3 months of category I TB regimen. Qualitative findings revealed the following challenges to detection and
enrollment of MDR-TB in Vietnam: insufficient TB screening capacity at district hospitals where TB units were not
available and poor communication and implementation of policy changes. Instructions for policy changes were not
always received, and training was inconsistent between training courses. The private sector did not adequately report
MDR-TB cases to the NTP.
Conclusions: The proportion of MDR-TB patients diagnosed and enrolled for second-line treatment is less than 20 %
of the estimated total. The low enrollment is largely due to the fact that many patients at risk are missed for MDR-TB
screening. In order to detect more MDR-TB cases, Vietnam should intensify case finding of MDR-TB by a
comprehensive strategy to screen for MDR-TB among new cases rather than targeting previously treated cases, in
particular those with HIV co-infection and contacts of MDR-TB patients, and should engage the private sector in PMDT.
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Background
Multidrug-resistant tuberculosis (MDR-TB) is a global
health concern as treatment is prolonged, costly, and less
effective compared to that of drug-susceptible TB. Glo-
bally, there are about 450,000 MDR-TB patients reported
with an estimated 170,000 MDR-TB-related deaths annu-
ally. Regarding the TB and MDR-TB epidemiology in
Vietnam, the country is ranked 12nd among 22 high bur-
den countries with TB, and 14th among 27 countries with
a high burden of MDR-TB. The incidence of TB in
Vietnam is estimated at 144 per 100,000 population per
year and the estimated prevalence is 209 cases per 100,000
population [1]. There are estimated to be about 5100
MDR-TB cases among notified TB cases per year. The
proportion of TB cases with MDR-TB among new and
retreatment cases is estimated to be 4 and 23 %, respect-
ively, with around 6 % among TB cases co-infected with
HIV [1]. A preliminary report from a TB drug resistance
survey conducted in Vietnam from 2011–2012 showed
that the estimated proportion of XDR-TB among MDR-
TB was 5.6 %. Of the MDR-TB patients, 16.7 % showed
resistance to fluoroquinolones (ofloxacin), 1.1 % to amika-
cin, 5.6 % to kanamycin, and 5.6 % to capreomycin (un-
published data).
In 2009, the Vietnamese government issued a policy
on MDR-TB following WHO recommendations to en-
hance and scale up diagnosis and treatment services for
MDR-TB [2]. It is based on the five essential control
components that constitute the already implemented
DOTS strategy for drug-susceptible TB. These compo-
nents include: sustained political commitment, rational
case finding, short-course treatment, an uninterrupted
drugs supply, and standardized recording and reporting
[3]. Since a pilot project in Ho Chi Minh City in 2009,
diagnosis and treatment services for MDR-TB have be-
come available in 35 of all 63 provinces by 2013. The
programmatic management of drug-resistant tubercu-
losis (PMDT) is more complex than for susceptible TB
as it requires greater human, financial and technical re-
sources [3]. Between 2009 and 2011 the Vietnam PMDT
program had a success rate, defined as MDR-TB patients
who completed treatment and were cured, of approxi-
mately 75 %. This rate is high compared to many other
countries reporting rates of 44–58 % [4, 5]. Despite that
the treatment outcome may depend on drug resistance
patterns, this high success rate does reflect good compli-
ance with the treatment regimen in Vietnam [6]. The
current standard second-line regimen is kanamycin,
capreomycin, levofloxacin, cycloserine, protionamide,
and para-aminosalicyclic acid (PAS).
However, the number of MDR-TB patients detected
and enrolled to second-line treatment is low compared
to the expected number among notified TB cases, based
on national drug susceptibility data [7]. This means that
only a few of the MDR-TB patients get diagnosis and the
recommended treatment. This can partly be explained
by the fact that Vietnam did not have nation-wide
PMDT coverage by 2013, and drug susceptibility testing
was not yet done for all notified TB cases. However,
PMDT was fully implemented in major cities by 2010,
where just 30–50 % of the total estimated MDR-TB pa-
tients were enrolled for second-line treatment. This find-
ing lead us to assess the proportion of MDR-TB patients
enrolled out of the estimated number of MDR-TB in all
PMDT areas of Vietnam in 2013 to determine the chal-
lenges to an efficient PMDT implementation and to pro-
vide recommendation to improve the PMDT enrollment.
PMDT includes five steps from diagnosis to treatment
for MDR-TB patients:(1) identification of presumptive
MDR-TB cases (individuals considered at high risk for
MDR- TB) according to case definitions, (2) referring
presumptive cases for diagnosis, (3) drug resistance test-
ing, (4) obtaining informed consent from patients for
treatment, and (5) enrollment of diagnosed MDR-TB pa-
tients to treatment. In this assessment, we used the data
reported by the national TB control program to focus
on three of these steps: identification of presumptive
MDR-TB cases, drug resistance testing, and enrollment
of diagnosed MDR-TB patients for treatment. Qualita-
tive investigation was used for assessment of steps (2)
and (4) and additionally to support the findings and their
interpretation for the other steps.
Methods
By 2013, 35 provinces had implemented the PMDT and
participated in the MDR-TB enrollment assessment.
Thirty-one provinces were selected by the NTP to im-
plement PMDT based on their prior MDR-TB case-load
and case management capacity. The remaining four
provinces with a low MDR-TB case-load were selected
as they had a high HIV prevalence. All 35 provinces
were provided access to diagnostic equipment for inten-
sified case finding using the Xpert MTB/RIF (Xpert)
assay, a within-cartridge real-time PCR assay that de-
tects M. tuberculosis as well as mutations in the rpoB
gene conferring resistance to rifampicin in clinical speci-
mens [8]. The selected provinces are required to provide
PMDT treatment services in case MDR-TB patients are
diagnosed. For the assessment, we reviewed all existing
reports and documents related to MDR-TB policies and
guidance since 2009 through December 2013.
A presumptive MDR-TB case requiring testing was de-
fined as belonging to at least one of the risk groups as
defined in the NTP guidelines (see Additional file 1). In
order to calculate the proportion of those screened for
MDR-TB, we divided the number of tested presumptive
MDR-TB cases by the number of presumptive MDR-TB
cases estimated using annual data reported by each
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province to the NTP (step1). All PMDT provinces pro-
vide quarterly reports to the NTP of the number of
Xpert MTB/RIF tests done and the number of MDR-TB
cases detected. We used the 2013 Xpert MTB/RIF data
for assessing the number of presumptive cases screened
per risk category (step 3).
For national estimation of MDR-TB, we used the num-
ber of all notified TB cases per province and applied the
result of the most recent national DRS in Vietnam (year
2011–2012) which showed prevalence of MDR-TB
among new and previously treated cases of 4.0 % and
23.0 %, respectively [1]. This allowed us to estimate the
expected number of incident MDR-TB cases in all prov-
inces irrespective of detection by the NTP. We used the
standard errors from the MDR-TB prevalence as esti-
mated in the DRS to calculate confidence intervals for
the proportion of MDR-TB patients enrolled for second-
line treatment in this study. The proportion with 95 %
confidence intervals (95 % CI) was estimated for the num-
ber of MDR-TB patients enrolled for second-line treat-
ment among (i) the estimated number of MDR-TB cases
in the whole country and (ii) the estimated number of
MDR-TB cases in the 35 PMDT provinces (step5).
This review was followed by focus group discussions
(FGD) in face-to-face workshops, which encompassed
five separate one-day sessions with approximately 30 key
provincial TB staff members (for all PMDT steps includ-
ing steps 2 and 4). FGD were used to discuss the PMDT
program, challenges to implementation and potential so-
lutions. Five groups were invited from eight different
geographic areas (see Additional file 1). TB staff in-
cluded provincial program managers, program officers
with expected knowledge of the local overall situation
and staff responsible for implementation of PMDT in
their province. Guidance was provided for FGD facilita-
tors who had previous FGD discussion experience and
knowledge of the NTP. Discussions were continued until
saturation was reached before facilitators moved to a
new topic. FGD summaries were checked and agreed
upon by all participants to be finalized for content ana-
lysis later on. The sessions were not audio recorded and
transcribed due to lack of funds.
Furthermore, in-depth interviews to supplement the
focus group discussions was conducted by the same
group of interviewers with eighty TB health staff at dif-
ferent levels of the NTP, including 8 central staff from
PMDT team, 56 provincial staff from variety of depart-
ments, and 16 district and commune level health staff
(for all steps). The interview guide was developed and
piloted before the interviews and included questions re-
garding: structure of the TB health unit at specific levels
in the health system, training provided to staff, their
knowledge and awareness about MDR-TB risk groups,
their role and job description, and challenges encountered
in PMDT implementation. The in-depth interview also
allowed the interviewee to reflect on findings from the
FGD. These interviews were conducted during monitoring
visits in 2014 in eight randomly selected provinces among
the 35 PMDT provinces from three zones: four provinces
were randomly selected from the southern zone as there
exists the highest disease burden, two from the north and
two from the centre (see Additional file 1). The interviews
were conducted privately. During the interview and FGDs,
detailed notes were taken and used subsequently to iden-
tify key themes. In the analysis, similarities and differences
between the various interviews and FGDs were looked for
and summarized to identify key findings. The interviews
were not recorded.
This study was approved by the research and ethics
committee of the National Lung Hospital in Hanoi. In-
formed consent was obtained from participants in work-
shops and in-depth interviews.
Results
The estimated number of MDR-TB cases in Viet Nam
Based on the notification report of the NTP in 2013 and
the results of the recent national DRS, we estimated that
in 2013 there were 5065 (95 % CI: 3355–6700) MDR-TB
patients among 102,196 notified TB cases, resulting in a
proportion of 5.0 % MDR-TB among notified cases for
the year 2013 (95 % CI: 3.3–6.6 %). These cases were
mainly concentrated in the South–East, Mekong Delta
and Red River Delta regions. The PMDT program
already covered provinces with an expected high number
of MDR-TB cases (Fig. 1 and Table 1). We estimated
that the majority 3982/5065 (78.6 %) of the national
MDR-TB case-load originates in the provinces partici-
pating in the PMDT (Table 1).
Identification of MDR-TB presumptive cases to be tested
(step 1)
In 2013, there were an estimated 18,165 cases identified
as presumptive MDR-TB nationally, with the majority
(n = 14,998) in the 35 PMDT provinces (82.6 %). There
was no data available on the number of MDR-TB pre-
sumptive cases identified by the health staff of PMDT
areas who were referred for screening.
Testing practices per risk category by Xpert MTB/RIF and
detection of MDR-TB (step 3)
A total of 32 Xpert MTB/RIF instruments were distrib-
uted among the 35 PMDT provinces. The estimated num-
ber of MDR-TB cases to be detected per machine per year
for these instruments varied by region, ranging from 9 to
338 MDR-TB cases (see Additional file 1). The instrument’s
capacity is expected to be sufficient as one instrument with
four modules is able to test approximately 3000 MDR-TB
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presumptive cases to detect around 500 rifampicin resistant
TB cases per year (see Additional file 1).
The proportion of MDR-TB presumptive cases tested
by Xpert MTB/RIF was 31.2 % (5668/18,165) for the
whole country and 37.8 % (5668/14,998) in the 35
PMDT provinces (Table 2). In PMDT provinces, the
highest proportion of MDR-TB presumptive cases tested
was in the North-West (43/46; 93.9 %) and the Southern
Central Coast (668/897; 74.5 %) regions. The lowest pro-
portions were in the Central Highlands (0/69; 0 %) and
the Mekong Delta (516/3935; 13.1 %; Table 2) regions.
In the North-West region, all provinces together only
had 43/214 (20.1 %) of presumptive cases tested while
that percentage was 43/46 (93.9 %) in the PMDT prov-
inces. Among 5668 MDR-TB presumptive cases tested,
997 cases were detected as rifampicin resistant (17.6 %).
The proportions of HIV infected TB cases and new
TB non-converters tested by Xpert MTB/RIF were
10.5 % (340/3224) and 13.1 % (290/2214), respectively
(Table 3). Retreatment patients who showed no sputum
conversion after 3 months of the category II regimen
were tested frequently: 85.7 % (413/482). We estimated
that 249/402 (62.0 %) of symptomatic household con-
tacts of MDR-TB patients were tested. Among 249
MDR-TB symptomatic household contacts screened
within 1 year after MDR-TB patients diagnosed, 77 TB
patients were detected (30.9 %) including 9 TB patients
resistant to rifampicin (3.6 %). We could not calculate
the testing rate among failure cases since no data were
available for the number of people tested. However, this
rate was estimated to be at least 68.5 % because one fail-
ure case could receive up to two tests.
Enrollment to second-line treatment (step 5)
Of 997 rifampicin-resistant cases detected, 948 (95.1 %)
were enrolled for MDR-TB treatment, accounting for
just 18.7 % (95 % CI: 14.1–28.3 %) of the estimated 5065
MDR-TB cases in the whole of Vietnam (Fig. 2). The re-
gion with the highest proportion of MDR-TB patient en-
rolled for second-line treatment was the South-East
region with 495/1546 (32.0 %; 95 % CI: 24.3–47.8 %),
followed by the Red River Delta with 234/859 (27.3 %;
95 % CI: 20.5–41.4 %). The lowest enrollments were in
the Mekong Delta region: 81/1288 (6.3 %; 95 % CI:
Fig. 1 Estimated number of MDR-TB patients among notified TB cases in Viet Nam, 2013
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4.8–9.5 %). No enrollments were reported in PMDT
for North-East, North-West and Central Highlands
(Table 1, Fig. 3). Also in the 35 PMDT provinces, the
enrollment proportion of MDR-TB cases was low: 948/
3982 (23.8 %; 95 % CI:18.0–35.9 %). The highest pro-
portion was seen in the PMDT provinces in the Red
River Delta with 234/627(37.3 %; 95 % CI: 28.2–
56.5 %), and South-East region: 495/1408 (35.2 %; 95 %
CI: 26.7–52.4 %)
Qualitative investigations (all steps)
This section reveals the challenges to a successful diagno-
sis and enrollment for treatment of MDR-TB (Table 4). It
was noted that TB units (i.e. small departments operating
under the NTP that identify MDR-TB presumptive, pro-
vide TB diagnostic and first-line treatment services by spe-
cifically trained staff) are located mainly in district health
centers. Although there is a policy change ongoing to have
TB units also in (district) hospitals this had not yet been
implemented in all districts. As a result, several district
hospitals, where many MDR-TB presumptive cases
present did not have TB diagnostic facilities and hospital
staff had not been trained and instructed to screen pa-
tients for TB and MDR-TB.
Provincial and district staff reported that they were
overall not well informed about PMDT procedures. The
first guideline for PMDT was issued in 2009 [2] and has
not been updated for any of the multiple changes since
then. The changes in policies over time had been up-
dated through separate instruction letters from the cen-
tral level and though yearly PMDT training courses
without documenting these in a clear set of guidelines.
A total of 17 instruction letters to inform about changes
have been sent out from central level to provinces be-
tween 2009 to late 2013. However, regularly these update
letters were not received by the provincial PMDT officer
or the information was not disseminated to the relevant
staff at lower levels. A further challenge was regular
health care staff turnover or change in health care staff ’s
responsibilities over time. As a consequence, it is
Table 2 Percentage of presumptive MDR-TB patients tested by regions
Ser. No Region Number of
presumptive
MDR-TB
patients tested
All provinces 35 PMDT provinces
Estimated Number of
presumptive
MDR-TB patients
% tested Estimated Number of
presumptive MDR-TB patients
% tested
1 Red River Delta 801 2,519 31.8 % 2,035 39.4 %
2 North-East 263 1,154 22.8 % 627 42.0 %
3 North-West 43 214 20.1 % 46a 93.9 %
4 Northern Central 460 1,144 40.2 % 886 51.9 %
5 Southern Central Coast 668 1,117 59.8 % 897 74.5 %
6 Central Highland 0 290 0.0 % 69 0.0 %
7 South -East 2,917 6,991 41.7 % 6,503 44.9 %
8 Mekong Delta 516 4,736 10.9 % 3,935 13.1 %
Total 5,668 18,165 31.2 % 14,998 37.8 %
aone PMDT province in North – West
Table 1 Actual enrollment and estimated total number of MDR-TB cases nationwide and in 35 PMDT provinces (the numbers in
brackets are for lower and upper CI)
Ser. No Region Number
enrolled
All provinces 35 PMDT provinces % estimated number
of MDR-TB covered
by PMDT provinces
Estimated number
of MDR-TB cases
% enrolled Estimated number
of MDR-TB cases
% enrolled
1 Red River Delta 234 859 (565–1,139) 27.3 (20.5–41.4) 627 (414–830) 37.3 (28.2–56.5) 73.0 %
2 North-East 0 339 (223–449) 0.0 189 (124–252) 0.0 56.0 %
3 North-West 0 53 (35–71) 0.0 9 (6–12) 0.0 17.0 %
4 Northern Central 54 466 (305–618) 11.6 (8.7–17.7) 338 (222–449) 16.0 (12.0–24.3) 72.7 %
5 Southern Central Coast 84 405 (266–536) 20.8 (15.7–31.5) 304 (200–403) 27.6 (20.8–41.9) 75.2 %
6 Central Highland 0 110 (72–146) 0.0 21 (14–27) 0.0 18.8 %
7 South -East 495 1,546 (1,035–2,036) 32.0 (24.3–47.8) 1,408 (944–1,854) 35.2 (26.7–52.4) 91.1 %
8 Mekong Delta 81 1,288 (854–1,704) 6.3 (4.8–9.5) 1,086 (720–1,436) 7.5 (5.6–11.3) 84.3 %
Total 948 5,065 (3,355–6,700) 18.7 (14.1–28.3) 3,982 (2,643–5,264) 23.8 (18.0–35.9) 78.6 %
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challenging to ensure training and skills development for
all the staff involved in TB and MDR-TB management.
Standard operating procedures (SOPs) for PMDT were
developed and released in 2012, three years since the
MDR-TB guideline was released. The SOPs lacked clear
instructions for steps that need to be taken [9]. No
standard PMDT training modules are available as the
training and presentations were prepared and updated
by different lecturers, based on their interpretation of
the available guidelines and SOPs. Inconsistencies across
training courses were mentioned by trained health staff,
which generated uncertainty. In addition, the majority of
district level staff was not trained due to lack of funding.
In 2013, the majority of district staff with an assigned re-
sponsibility to identify presumptive MDR-TB had not
been trained to identify risk groups. Supervision visits
conducted between April and July 2014 revealed that,
although all districts under PMDT had been trained,
their focus was on retreatment cases, while non-
converters among new cases and HIV-positive TB pa-
tients were generally neglected.
Many TB units were unable to send sputum for testing
by Xpert MTB/RIF as no appropriate financial compen-
sation mechanisms were in place for consumable pro-
curement and sputum transportation fees. Partly this
was due to a delay in an award from the Global Fund. In
addition it was not straightforward to send specimens by
mail as no agreements with the postal services were in
place, and sputum referral using health staff or public
transportation were used instead. This may explain why
in some regions with Xpert MTB/RIF capacity, like the
Mekong delta region, the proportion tested and enrolled
was limited. Finally, there had been stock outs of Xpert
MTB/RIF test kits due to delays in cartridge forecast
Table 3 Presumptive MDR-TB patients estimated and tested by risk category in the whole country and in 35 PMDT provinces of
Vietnam 2013
Presumptive category Estimate number for whole
countrya
Estimate number for PMDT
areas only
Number of Xpert tests
performed
% tested in PMDT
areas
Retreatment Failureb 593 519 711 ND
Relapse 7,059 5,673 2,641 46.6 %
Defaulters 472 376 129 34.3 %
Other 739 662 210 31.7 %
Non-converters at 2 and
3 months
New 2,713 2,214 290 13.1 %
Retreatment 586 482 413 85.7 %
MDR contacts 402 402 249 62.0 %
TB/HIV 3,828 3,224 340 10.5 %
>1 month using TB drugs 1,773 1,446 685 47.4 %
Total MDR-TB suspects 18,165 14,998 5,668 37.8 %
aThe denominator is the number of presumptive by categories that need to be tested
bFailure is defined as sputum smear positive at 5 months or later during treatment, so one failure case could receive one or 2 tests (at 5 and/or 7 months). ND:
not done as failure cases can be tested on multiple occasions
Fig. 2 PMDT performance for case detection and enrollment of MDR-TB in Vietnam
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reporting. Although challenges were mentioned for
sending sputum, there was always a confirmation and
communication between referring sites and laboratory
after samples had been sent. A small number of referred
samples were rejected by the laboratory for being con-
sidered low-quality or low-volume, and requested to re-
collect and re-send.
For MDR-TB patients that were diagnosed, health staff
mentioned that informed consent was obtained for all of
these patients before starting treatment. There were is-
sues regarding enrolling MDR-TB patients for treatment
due to lack of hospitalization capacity. It was reported
that poor links existed between the public and private
sector, as patients cannot be referred from the private to
the public sector to continue their treatment. Further-
more, there are no management systems in place to
screen and treat MDR-TB patients in prison (see Table 4
for more details).
Discussion
We estimated that only one third of MDR-TB presump-
tive cases are screened by Xpert MTB/RIF in Vietnam.
However, it is encouraging that 95 % of the patients who
were tested positive for MDR-TB were enrolled for
second-line treatment. The low enrollment rate is mainly
attributable to low number of presumptive MDR-TB cases
identified and subsequently tested, and not due to poor
enrollment of patients after diagnosis. There were some
inconsistencies between the percentage of MDR-TB pre-
sumptive cases tested in 35 PMDT provinces (Table 2)
and the enrollment rate of MDR-TB (Table 1). While
there were relative high testing proportion in the North-
East, North-West, Northern Central and Southern Central
Coast regions, the enrollment proportion for treatment
among number estimated were low, varying from 0 % to
27.3 %. In other regions, the variations in enrollment rates
were in line with the variations in percentage of MDR-TB
Fig. 3 The enrollment proportion into the second-line treatment program of MDR-TB cases among the estimated number of notifiable MDR-TB
cases in 35 PMDT provinces in 2013. Data are presented per socio-economic region
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presumptive cases tested. The reasons behind these incon-
sistencies were limited capacity for hospitalization and
other issues as revealed by our qualitative assessment.
This study showed that access to Xpert MTB/RIF test-
ing was overall sufficient for Vietnam. However, regions
with a higher number of operational Xpert MTB/RIF in-
struments had a higher enrollment proportion compared
to regions with fewer instruments, except for the Mekong
River Delta (Fig. 3). While the burden of MDR-TB in Me-
kong Delta region was high, with Xpert MTB/RIF instru-
ments widely available, the enrollment proportion in this
region was very low: 7.5 % (Table 1, Fig. 3). The reason be-
hind the low enrollment proportion in Mekong Delta re-
gion is a weak system for transferring specimens for Xpert
MTB/RIF testing as revealed by our qualitative study. In
addition, procurement of test kits needs improvement to
avoid stock outs, and redistribution of Xpert MTB/RIF in-
struments from the Red River Delta with 9 instruments
and a low workload to the Northern Central region with
just one instrument and a high workload may improve ac-
cess to testing for risk categories. Testing coverage was
nil in the Central Highlands region. Although this area
has a relatively low number of estimated MDR-TB
cases, facilitating a good specimen referral system for
testing could increase the coverage. Main challenges
for effective MDR-TB diagnosis and treatment and po-
tential solutions proposed by our study team for under
enrollment are listed in Table 4.
New TB patients whose sputum had not converted
after 2 or 3 months of treatment and TB patients with
HIV, both considered risk groups for MDR-TB, were
largely neglected for screening and had the lowest pro-
portions of MDR-TB screening done while they account
for the majority of presumptive MDR-TB cases [2, 3].
Since the proportion of detected rifampicin-resistant pa-
tients among these groups in 2013 was 11.3 % [10], it is
likely that a considerable number of MDR-TB remain
undiagnosed due to inadequate screening among these
groups. Importantly, undetected MDR-TB/HIV patients
who have high mortality rates [11, 12] would lose the
opportunity for adequate treatment. Moreover, TB-HIV
patients in 2013 are underreported due to limited collab-
oration between the TB and HIV control programs [13].
The qualitative assessment revealed that many pa-
tients refuse treatment in units far from home. Other
patients reported problems getting health insurance re-
imbursement in case they were referred to another
province. Lack of collaboration between treatment cen-
ters and adjacent provinces for referring patients for
treatment also contributed to drop outs. Another con-
tributing factor to treatment delays and poor enrollment
was the irregular delivery and stock outs of MDR-TB
treatment drugs due to procurement delays. Occasion-
ally, patients insisted to be enrolled, but they had to wait
for a long time to start treatment.
This study also revealed poor links between the public
and private sector. Due to absence of a referral mechan-
ism between the two systems, MDR-TB presumptive were
not referred from private sector to the NTP for diagnosis,
and patients who withdrew from MDR-TB treatment in
Table 4 Obstacles to enrolling MDR-TB patients for treatment and solutions for an effective PMDT
Ser. No Obstacle Proposed solution
1 A set of key documents is lacking: updated guidelines, concise and
clear SOPs, and standard training modules.
The NTP is strongly recommended to ensure that key documents are
prepared and circulated to appropriate staff, with proper training.
Letters with updates should be discouraged, unless there is an
urgency.
2 Failures in identifying presumptive MDR-TB cases for screening. The development of consistent training modules in accordance with
national guidelines and SOPs.
3 Absence of a sound referral system for sending sputum samples to a
laboratory.
A sound national referral system should be set up with a shipping
agency who can do this safely.
4 Current Vietnam policy is to require patient to be hospitalized at the
start of treatment. However, there is insufficient hospitalization
capacity and patients may refuse to be referred to another treatment
centre in another province either due to distance from hometown or
additional costs without getting health insurance reimbursement.
The NTP policy needs consider the adoption for ambulatory treatment
with community based care as also recommended by WHO [3]. Health
insurance need to support MDR-TB patients in reimbursing costs in case
there is a need for referral to another province for PMDT treatment.
5 Temporary MDR-TB drug stock-out due to procurement and distribution
delay resulted in patients either not enrolled for treatment or a delay in
treatment.
Improve drug procurement and distribution system.
6 TB units in many districts remain located in health centers that focus
on prevention, and are separate from the general hospitals, which is
discrepant from MoH policy.
Enforce policy to locate TB units in the district general hospitals.
Training should be provided to appropriate staff.
7 Poor links between the NTP and public sector and no management
system for MDR-TB patients in prison. There is no mechanism to refer
MDR-TB presumptives or MDR-TB patients from the private sector to
the NTP to be diagnosed or for treatment. The private sectors often
do not notify MDR-TB cases to the NTP.
Establish the collaboration between the private sector and PMDT.
Ensure private sector adheres to treatment guidelines for TB and
MDR-TB. Provide diagnosis and treatment service for MDR-TB patients
in prison.
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the private sector for financial or other reasons were un-
able to enroll to continue treatment in the public PMDT.
Currently, only limited data for MDR-TB patients in the
private sector are available, where default rates are high,
up to 75 %, implying poor MDR-TB management in the
private sector that may lead to drug resistance amplifica-
tion [14]. Also MDR-TB patients in prisons pose a chal-
lenge as second-line treatment is not available, and no
procedures for management of MDR-TB patients after
discharge from prison are in place.
The current PMDT policy is that each district should
have a TB unit. The Ministry of Health has as a policy to
locate TB units in general hospitals, or in district health
centers if a general hospital is not present [15]. This pol-
icy is aimed at strengthening the utilization of diagnosis
and treatment services for TB units in the district hos-
pital, where most patients seek health care. However,
our study found that not all district hospitals have a TB
unit with TB screening capacity. Health staff lack proper
training and MDR-TB screening skills and do not have
access to updated guidelines/SOPs to support them in
identifying patients. This results in confusion and lim-
ited confidence among staff to implement the PMDT
properly. Inconsistencies across training courses also
contributed to confusion around the PMDT policies.
Clear guidelines, instructions and training for health
staff is needed to improve this.
Our study has several limitations. To estimate the
MDR-TB enrollment proportion we used two different
data sets: the 2013 NTP report and the DRS conducted
in 2011–2012. For the number of MDR-TB cases de-
tected, we only used laboratory reports from Xpert
MTB/RIF testing and we did not include reports from
other tests such as line-probe assays or phenotypic drug
susceptibility testing. As the number of tests done by
these other methods is small, less than 5 % with consid-
erable overlap with Xpert MTB/RIF testing, we decided
to exclude these.
Furthermore, as we do not know the prevalence of ri-
fampicin resistance for each MDR-TB risk group we could
not assess the positive predictive value (PPV) of Xpert
MTB/RIF separately among each category of presumptive
MDR-TB patients. However, for most categories, the esti-
mated prevalence of rifampicin resistance is relative high
(around one-fourth, given the 23 % prevalence among pre-
viously treated patients in the DRS). In addition, recent
studies from South Africa [16] and Brazil [17] suggest a
PPV on the order of 90 % even with relatively low preva-
lence of rifampicin resistance. Therefore we do not ex-
pect that the PPV in our study will have been much
below 90 %, and thus did not affect the results to con-
siderable extent.
A final limitation is that we did not involve the private
sector in our study. However, our qualitative assessment
suggests poor management of MDR-TB in the private
sector and a lack of a good referral system between the
private and public sector. This situation causes patients
to be under screened, poorly treated, and underreported
to the NTP. Better links need to be established between
the private and public sector.
Conclusion
The proportion of MDR-TB patients enrolled for
second-line treatment among the total estimated num-
ber of MDR-TB cases in Vietnam in 2013 was 18.7 %
(948/5065). The low enrollment was considered due to
under-screening of MDR-TB presumptive cases, espe-
cially for HIV infected and new TB non-converters.
Multiple reasons exist for under-screening, including:
poor communication and implementation of policy
changes, lack of involvement of general district hospitals,
and limited resources. However, Vietnam has achieved a
high proportion of enrollment to second-line treatment
among of detected MDR-TB cases and a high treatment
success rate, which can be considered an opportunity to
mobilize resources and expand the program to detect
and treat more MDR-TB cases. Vietnam should expand
the intensified case finding of MDR TB by a comprehen-
sive strategy with more focus on new detected cases, in
particular those with HIV co-infection and contacts of
MDR-TB patients. The capacity to treat new MDR-TB
cases will need to be increased in case the screening is
improved. The private sector needs to be engaged in the
PMDT.
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